Suchergebnisse - "Jackson, David J"

PubPharm (18)

1

Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis

enthalten in: The New England journal of medicine | 2024

von Wechsler, M. | Nair, P. | Terrier, B. | +114

2

Long-Term Effectiveness of Benralizumab in Eosinophilic Granulomatosis With Polyangiitis

enthalten in: The journal of allergy and clinical immunology. In practice | 2024

von Nanzer, A. | Maynard-Paquette, A. | Alam, V. | +16

3

Reduction of daily maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab (SHAMAL) : a randomised, multicentre, open-label, phase 4 study

enthalten in: Lancet (London, England) | 2024

von Jackson, D. | Heaney, L. | Humbert, M. | +41

ErratumIn: Lancet. 2024 Mar 23;403(10432):1140. - PMID 38521558

4

Comparative effectiveness of anti-IL5 and anti-IgE biologic classes in patients with severe asthma eligible for both

enthalten in: Allergy | 2023

von Pfeffer, P. | Ali, N. | Murray, R. | +66

5

COVID-19 in the absence of eosinophils : The outcome of confirmed SARS-CoV-2 infection whilst on treatment with benralizumab

enthalten in: Allergy | 2022

von Francis, C. | Hearn, A. | Ratnakumar, S. | +6

6

Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose

enthalten in: The journal of allergy and clinical immunology. In practice | 2022

von Domingo, C. | Maspero, J. | Castro, M. | +12

7

Benralizumab Effectiveness in Severe Asthma Is Independent of Previous Biologic Use

enthalten in: The journal of allergy and clinical immunology. In practice | 2022

von Jackson, D. | Burhan, H. | Menzies-Gow, A. | +7

8

Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE) : a multicentre, open-label, single-arm study

enthalten in: The Lancet. Respiratory medicine | 2022

von Menzies-Gow, A. | Gurnell, M. | Heaney, L. | +13

ErratumIn: Lancet Respir Med. 2021 Dec;9(12):e114. - PMID 34695373

9

Adherence to inhaled corticosteroids and clinical outcomes following a year of benralizumab therapy for severe eosinophilic asthma

enthalten in: Allergy | 2021

von d'Ancona, G. | Kavanagh, J. | Dhariwal, J. | +8

10

Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma

enthalten in: Allergy | 2021

von Kavanagh, J. | Hearn, A. | d'Ancona, G. | +8